This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Biotie Therapies Corp.
Drug Names(s): BTT1023, VAP-1 Antibody
Description: BTT-1023 is a fully human monoclonal antibody targeted against the Vascular Adhesion Protein-1 (VAP-1) receptor. Inhibiting VAP-1 is thought to reduce inflammation by regulating the migration of leukocytes, or white blood cells, to inflamed tissues.
Biotie and Roche
In November 2006, Biotie signed an option agreement with Roche for the antibody program targeting VAP-1. Under the terms of the agreement, Roche has paid an option initiation fee of EUR 5 million, which grants Roche an exclusive option right to an exclusive, worldwide license agreement for Biotie's fully human antibody targeting VAP-1, excluding Japan, Taiwan, Singapore, New Zealand, and Australia. The initial option right will end upon completion of Phase I trials. Roche may extend the option right to later development points by paying additional fees. Biotie will retain all rights to the program until a license is granted to Roche.
In April 2010, Biotie announced that Roche has decided not to exercise its opt-in right for BTT-1023.
Biotie and Seikagaku
Seikagaku Corporation has licensed the rights for BTT-1023 in Japan, Taiwan, Singapore, New Zealand, and Australia and could pay up to USD 16.7 million in milestone payments plus...See full deal structure in Biomedtracker
Additional information available to subscribers only: